In spite of continuous improvements in device design and applications, the profound use of heart pump has been limited because of its high price. The available clinically applied heart pump costs mostly about 100 thousands US Dollars. The author has since long tried to develop a heart pump costing only 1000 Dollars for recovery or bridge to heart transplantation therapies. The device is a radially driven centrifugal pump with a brush-less DC motor and a streamlined impeller. Its bearing is rolling bearing using 4 to 6 needles, manufactured by special wear-proof polythene with super-high-molecular weight, thus the service life achieves more than 10 years. To avoid thrombus formation, a special purge system is introduced to the bearing, allowing the saline with heparin to be infused through the bearing into the pump. The bearing, therefore, keeps working in the saline, and absolutely no thrombus will be formed along the bearing. Animal experiments demonstrated that a 30 mL fluid infusion per hour is enough to prevent thrombus formation. With these improvements, the impeller pump has continuously run for 14 months in the laboratory, and no bearing wear can be measured. The device, weighing 150 g, is fully implantable, consumes approximately 9.6 W, delivers a 9Lmin-1 blood flow against a 120 mmHg mean pressure, and reaches a highest total efficiency of 24.7% for the motor (including the controller) and the pump. The device has been used in animal experiments together with an American artificial lung for more than one month in the University of Texas and also in human trials in the Taiwan University.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2701075 | PMC |
http://dx.doi.org/10.2174/1874120700701010011 | DOI Listing |
JMIR Res Protoc
January 2025
School of Exercise and Nutrition Sciences, Institute for Physical Activity and Nutrition, Deakin University, Burwood, Australia.
Background: Heart failure (HF) is a chronic, progressive condition where the heart cannot pump enough blood to meet the body's needs. In addition to the daily challenges that HF poses, acute exacerbations can lead to costly hospitalizations and increased mortality. High health care costs and the burden of HF have led to the emerging application of new technologies to support people living with HF to stay well while living in the community.
View Article and Find Full Text PDFActa Bioeng Biomech
June 2024
1Department of Biomedical Engineering, Hefei University of Technology, Hefei, People's Republic of China.
: The utilization of intra-aortic balloon pump (IABP) and Impella has been suggested as means of left ventricular unloading in veno-arterial extracorporeal membrane oxygenation (VA-ECMO) patients. This study aimed to assess the local hemodynamic alterations in VA-ECMO patients through simulation analyses. : In this study, a 0D-3D multiscale model was developed, wherein resistance conditions were employed to define the flow-pressure relationship.
View Article and Find Full Text PDFCureus
December 2024
Department of Anaesthesia and Intensive Care, Latifa Hospital, Dubai Health, Dubai, ARE.
We describe, to our knowledge, the first use in Dubai of extracorporeal life support (ECLS) in a patient who suffered intraoperative cardiac arrest due to presumed cardiac channelopathy. A 40-year-old patient presented for open myomectomy surgery. She had no other medical problems apart from obesity.
View Article and Find Full Text PDFJ Cardiothorac Surg
January 2025
Department of Surgery, Division of Cardiac Surgery, Jefferson-Einstein Medical Center Philadelphia, Philadelphia, PA, USA.
Background: End-Stage Renal Disease (ESRD) is an independent risk factor in outcomes for traditional coronary artery bypass grafting (TRAD-CAB) utilizing aortic cross-clamping and cardioplegic arrest. In order to determine if Beating-Heart CABG (BH-CABG) techniques offer benefit in patients with ESRD, an analysis of the Society of Thoracic Surgeons (STS) predicted risk versus the actual outcomes was performed.
Methods: Between March 2017 - October 2023, all ESRD patients underwent BH-CABG by a single surgeon at a single institution.
Cardiovasc Eng Technol
January 2025
Institute for Medical Engineering and Science, Massachusetts Institute of Technology, MA, Cambridge, USA.
Purpose: Atrial fibrillation (AF) is the most common chronic cardiac arrhythmia that increases the risk of stroke, primarily due to thrombus formation in the left atrial appendage (LAA). Left atrial appendage occlusion (LAAO) devices offer an alternative to oral anticoagulation for stroke prevention. However, the complex and variable anatomy of the LAA presents significant challenges to device design and deployment.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!